Ref ID: 17757
Author:
N.P. Wiederhold*, P.A. Warn, L.K. Najvar, J. Livermore,
R. Bocanegra, W.R. Kirkpatrick, T.F. Patterson
Author address:
(San Antonio, US;
Manchester, UK)
Full conference title:
22nd European Congress of Clinical Microbiology and Infectious Diseases
Abstract:
Objective: Murine models of invasive candidiasis are frequently used
in the preclinical evaluation of investigational antifungals as these
models are typically robust and inexpensive. However, there have been
few inter-laboratory studies of outcome variability with the same
model. Our objective was to conduct an inter-laboratory comparison of
treatment response between two laboratories (UTHSCSA and
University of Manchester) using a murine model of invasive
candidiasis with two different C. albicans clinical isolates.
Methods: Immunocompetent 30 g outbred ICR or CD1 mice were
inoculated intravenously with C. albicans SC5314 or ATCC 90028
(target starting inocula 1.5 · 105 and 1.5 · 106 cells/mouse,
respectively). Antifungal therapy began 1 day later and continued for
5 days. Treatment groups consisted of control, fluconazole (FLC)
10 mg/kg PO QD, and caspofungin (CFG) 1 mg/kg IP QD. Treatment
continued until day 5 and mice were followed off therapy until day 21
to assess survival. Kidneys and brains were collected on day 8 in the
fungal burden arm. Fungal burden was assessed by colony-forming
units (CFU), and survival was assessed by Kaplan-Meier analysis. Each
laboratory evaluated both isolates and conducted the experiments
independently.
Results: Antifungal response, as measured by reductions in kidney
fungal burden and improvements in survival, was very similar between
the two laboratories (Table). CFG significantly improved survival and
Abstract Number: NULL
Conference Year: 2012
Link to conference website: NULL
New link: NULL
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
Teclegiorgis Gebremariam [MS]1, Yiyou Gu [PhD]1, Sondus Alkhazraji [PhD]1, Jousha Quran1, Laura K. Najvar [BS]2, Nathan P. Wiederhold [PharmD]2, Thomas F. Patterson [MD]2, Scott G. Filler [MD]1,3, David A. Angulo (MD)4, Ashraf S. Ibrahim [PhD]1,3*,
2024
91
n/a
-
v
Ruta Petraitiene (US)
2024
90
n/a
-
v
Fabio Palmieri (CH), Junier Pilar
2024
89
n/a
-
v
Evelyne Côté (CA)
2024
88
n/a
-
v
Eliane Vanhoffelen (BE)
2024
87
n/a
-
v
Teclegiorgis Gebremariam, Yiyou Gu, Eman Youssef, Sondus Alkhazraji, Joshua Quran, Nathan P. Wiederhold, Ashraf S. Ibrahim
2024
86
n/a
-
v
Thomas Orasch (DE)
2024
85
n/a
-
v
Julien Alex, Katherine González, Gauri Gangapurwala, Antje Vollrath, Zoltán Cseresnyés, Christine Weber, Justyna A. Czaplewska, Stephanie Hoeppener, Carl-Magnus Svensson, Thomas Orasch, Thorsten Heinekamp, Carlos Guerrero-Sánchez, Marc Thilo Figge, Ulrich S. Schubert, Axel A. Brakhage
2024
84
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
83
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
82
n/a